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Cardiology

Prestigious $11.6M Grant Supports
Study of Heart Failure

JG 09-1179

The National Heart, Lung, and Blood
Institute (NHLBI) has awarded Jefferson
scientists an $11.6 million grant for the
study of cardiac injury and repair. Three of
the four labs funded by the grant are part
of the Department of Medicine’s Center for

Translational Medicine, which oversees the
department’s research activities. The fourth
lab belongs to Steven R. Houser, Chair of
the Department of Physiology at Temple
University Medical Center.
Principal Investigator for this programmatic
award is Walter J. Koch, PhD, the W. W.
Smith Professor of Medicine and Director
of the Center for Translational Medicine;
Dr. Koch is also Director of the Center’s
George Zallie and Family Laboratory of
Cardiovascular Gene Therapy. “Much of
the project will focus on the science of
cardiac failure and repair with the goal of
understanding and developing new therapies,”
says Dr. Koch. “We are also working with
stem cells and pharmaceuticals that patients
already receive.”
The study examines molecular mechanisms as
well as the potential for processes that might
repair a failing heart in adults, in the hopes of
generating data that could eventually result
in new therapies. Along with Dr. Koch (at
far left), support in administrative, surgical,
molecular cell biology, and gene therapy will
come from Center faculty members (see left;
clockwise from top right: Andrea Eckhart,
PhD; Joseph Rabinowitz, PhD; Ehre Gao,
MD, PhD; and Patrick Most, MD).
Continued on page 6

From the

Chairman
These pages profile the
kinds of impressive
accomplishments in
research, education, and
patient care that make me
proud to lead Jefferson’s
Department of Medicine.
On the research front,
we are honored to announce that Dr. Koch and
a team of Jefferson scientists were awarded an
$11.6 million grant from the National Heart,
Lung, and Blood Institute to study cardiac injury
and repair. In the clinical arena, our Cardiology
Division was recognized for its outstanding
performance in meeting the quality standards set
forth by the Centers for Medicare and Medicaid
Services. In education, the Internal Medicine
Clerkship Program, under Dr. Diemer’s direction,
demonstrates our commitment to deepening
students’ medical education. Other articles feature
the important work of Dr. Bergmeier and division
chiefs Dr. Cheung and Dr. Irigoyen.
I would like to thank several of the generous
donors (featured on page 5) who play an invaluable
role in supporting our initiatives. Together, our
researchers, clinicians, educators, and supporters
are the substance behind the Department of
Medicine’s well-regarded reputation. Please also
visit our department website at www.jefferson.edu/
medicine for more in-depth articles and updates
on our activities.
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4th Annual
Symposium
The Center for Translational Medicine’s annual
symposium, held June 5, 2008, showcased the
Center’s diverse interests in translational
science ranging from pulmonology, hematology,
rheumatology, and developmental biology to
the cardiovascular field. ■

Presenting scientists and organizing committee of
the Center for Translational Medicine’s 4th annual
symposium: Front row, left to right: Que-Xian Zhang,
PhD; X. Li, PhD; Yanrong Su, PhD; Jee In Kim, PhD;
Wolfgang Bergmeier, PhD; Raihana Zaka, PhD. Back
row, left to right: Donjun Li, PhD; Susan Moraca;
Walter J. Koch, PhD (Director of the Center for
Translational Medicine); A. Kondkar, PhD; Carolin
Kraus, MD; Dave Harris, PhD; Paulina Oca, MS;
Patrick Most, MD (Symposium Director); Yajing
Wang, MD, PhD; David Rohde, MD; Stephen B.
Liggett, MD (keynote speaker); Jeffrey Martini, PhD.

Center News
Patrick Most, MD (far right), Assistant
Professor and Director of the Laboratory for
Stem Cell and Gene Therapy at the Center
for Translational Medicine, received an
NIH Research Project Grant (or RO1) for
more than $1.9 million. The study is entitled
“S100A1: A novel modulator of myocardial
infarct inflammation and regeneration.”
Dr. Most began work in April 2008 and the
grant runs through March 2013.
On May 9, 2008, Heather I. Cohn successfully
defended her PhD dissertation, entitled “The
role of GRK2 in high blood pressure,” making her the first doctoral student to graduate
from the Center. Her advisor was Associate
Professor Andrea Eckhart, PhD, Director of
the Center’s Eugene Feiner Laboratory for
Vascular Biology and Thrombosis.
On March 28, 2008, Washingtonpost.com
featured a story about the Center for
Translational Medicine’s basic research on the
signaling protein called Gi and its critical role
in protecting the heart during a heart attack.
The full findings were published in the March
18, 2008, issue of the journal Circulation.

Keynote speaker Stephen B. Ligget, MD (above,
left), Professor of Medicine and Physiology receives
the Excellence in Translational Science Award 2008
in appreciation of his outstanding contributions to
translational cardiovascular and pulmonary research
from the Director of the Center for Translational
Medicine and W.W. Smith Professor of Medicine
Walter J. Koch, PhD (above, right).

Paulina Oca, MS
(above) and David
Harris, PhD (right)
received the
4th Center for
Translational Medicine Excellence in Science Award
for their presentations “TGFβ regulation of ANKH
(progressive ankylosis) expression in ATDC5 cells”
(Ms. Oca) and “Targeted inhibition of Gq-signaling
improves beta-adrenergic receptor mediated cardiac
function following hypertension” (Dr. Harris).

For more, see www.jeffersonhospital.org/
news/2007/article15918.html. ■
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Hematology

New Research Examines the Science Behind Blood Clots
Wolfgang Bergmeier, PhD, runs a laboratory
in Jefferson’s Curtis Building with two other
researchers that focuses on the problem of
thrombosis (blood clotting) at a molecular
level. After doing undergraduate work in
his native Germany, he did postgraduate
training at Harvard Medical School and
the Immune Disease Institute. He joined
Jefferson in early 2008 to build upon the
Division of Hematology and the research
program at Jefferson’s Cardeza Foundation
Hemophilia Center.

Investigating Arterial Thrombosis
Dr. Bergmeier’s work deals with the signaling
pathways regulating platelet activation and
adhesion. Platelets are best known for their
critical role in arterial thrombosis, that is,
in pathological conditions such as heart
attack and stroke. “Arterial thrombosis
is the formation of a thrombus within an
artery, a process driven by the uncontrolled
accumulation of platelets,” says Dr.
Bergmeier. “If these thrombi grow too

therefore thrombus formation. “The agents
used to prevent arterial thrombosis are platelet
inhibitors,” he explains. They aim at blocking
platelet adhesion, and some directly target
integrins, the adhesion receptors expressed on
the platelet surface (such as ReoPro®). Others
inhibit molecules important for the activation
of these receptors (such as aspirin or Plavix®).
“The problem of anti-thrombotics,” says Dr.
Bergmeier, “is that they also affect hemostasis,”
which is the physiological process whereby
bleeding is halted. “So the question becomes
whether a drug can effectively block thrombosis
while not significantly affecting hemostasis.”

Understanding Integrin Activation
To begin to answer this question, the lab has
made major progress in the regulation of
platelet integrins, the receptors on the surface
of the cell that act as a kind of Velcro that
binds the cells together. “When the platelets
get sticky enough,” Dr. Bergmeier says, “they
start forming thrombi. And while this is
crucial for hemostasis, it also can cause a heart

Wolfgang Bergmeier, PhD, leads a research team in Hematology that studies new ways to prevent arterial thrombosis.

big, they can obstruct blood flow through
the circulatory system, leading to ischemia
and infarction of vital organs such as the
heart or the brain. Coronary heart disease is
responsible for 1 in 5 deaths in the U.S., and
ischemic heart disease is still the leading cause
of death in developed countries.”

Issues of Anti-Thrombotics
Dr. Bergmeier’s lab is currently studying
new ways to inhibit platelet adhesion and

attack or a stroke. The signaling cascades
regulating integrin activation are complex
and interlinked, but there has been substantial
progress in identifying the important players
in this process,” he says.
Dr. Bergmeier’s recent work has identified
a protein called CalDAG-GEFI as one of
these central regulators of integrin activation
in platelets. “Our studies demonstrate
that CalDAG-GEFI is important for the
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near-immediate activation of integrins
in stimulated platelets, a process that is
absolutely required for the cell to adhere at
the site of vascular damage,” he says. Dr.
Bergmeier has published related articles
in Nature Medicine, the Journal of Clinical
Investigation, and Blood.
This basic research studies platelet function in
mice and is done in vitro (outside the animal)
and in vivo (inside the animal). He uses a
cutting-edge intravital microscopy approach
to study thrombus formation in arterioles of
living mice. “It’s still a mouse model, so we
have to be careful when we make predictions
on how successful targeting a particular
protein would be in humans,” he says. “But
studying platelet adhesion to sites of vascular
damage in vivo, or under most physiological
conditions, has become the gold standard for
evaluating new targets.”

Targeting Proteins
Dr. Bergmeier’s studies suggest that CalDAGGEFI cooperates with P2Y12, the target of
the antithrombotic drug Plavix®, in various
aspects of platelet activation. His studies
suggest that targeting CalDAG-GEFI may
be more effective than Plavix with regard
to reducing thrombus formation. He is
currently validating these observations in
other models of arterial thrombosis. “We are
very excited about our collaboration with
Dr. Force of the Center for Translational
Medicine, which will allow us to evaluate
the importance of CalDAG-GEFI in mouse
models of myocardial infarction and
ischemia-reperfusion injury in the heart. We
are convinced that targeting CalDAG-GEFI
could be a very powerful approach to interfere
with these illnesses.”
“Jefferson is an exciting place to be right
now,” says Dr. Bergmeier, given its core
group of people in the division who focus on
platelet biology and platelet-driven diseases.
“We also have a long tradition of caring for
patients with bleeding and clotting disorders
in our Hemophilia and Thrombosis Center.
And the Center for Translational Medicine is
one of the leading research institutions in the
country with regard to understanding heart
failure and heart disease. What we are starting
to do now is to combine our forces.” ■
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Nephrology

From Patient Rounds to Mouse Cell Research:
Nephrology Chief Covers All the Angles
The Department of Medicine benefits greatly
from leaders who pair leading-edge research
with clinical excellence. Joseph Cheung, MD,
PhD, who joined Jefferson in October 2006
as Chief of the Division of Nephrology and
the Capizzi Professor of Medicine, embodies
this dual commitment. In addition to his
long list of responsibilities as Division Chief
— overseeing the finances of the division,
expanding its activities, and recruiting new
faculty — Dr. Cheung also routinely sees
patients and conducts an extensive program
of NIH-funded cardiovascular research.
In the two years under Dr. Cheung’s
leadership, Nephrology has increased from
five to ten faculty members, and he has
expanded the division’s clinical activities
as well as its profile. In addition to threemonth rotations on inpatient nephrology
consultation, he works the same number

student at Penn State that Dr. Cheung met
his wife, Barbara A. Miller, MD, now the
Four Diamonds Professor of Pediatrics, ViceChairman of Pediatric Research, and Chief of
Pediatric Hematology/Oncology at Penn State.
She is Principal Investigator on NIH-funded
research on hematopoiesis.

heart, which not only controls the force of
the heartbeat but can generate irregular heartbeats under pathological circumstances. “It
is critical to understand this ion exchanger,
especially when its function has been altered,”
asserts Dr. Cheung.

Dr. Cheung’s training included a Medicine
Residency at Duke and Nephrology Fellowship
at Massachusetts General Hospital; he
subsequently obtained faculty positions at
Harvard and later Penn State, where he rose to
Professor of Medicine (tenured) in 1991 and
Chief of Nephrology in 1993. In 2000, to refocus and retool his research skills, Dr. Cheung
became Senior Scientist at the Weis Center for
Research at Geisinger Medical Center. He was
also named Director of Geisinger’s Pancreas
Transplant Program in 2003.

His work in the Center for Translational
Medicine involves isolating single cardiac
cells and placing them in culture. “Mice offer
unique advantages to the researcher because
their genes are much easier to manipulate
than those in larger animals,” Dr. Cheung
explains. Yet mouse heart cells are very
difficult to isolate and culture. “We put
genetically altered heart cells in culture, and
then use a virus to alter the expression of
another gene of interest — at least in the
short term.”

Heart Cell Remodeling

The work of Dr. Cheung’s lab is breaking
ground in two areas. “Ours is the first lab to
show that mouse heart cells retain normal
contractility in culture for 48 hours,” he
says, whereas previous research had shown
contractility and other function for only 24
hours. “Pictures taken at day two show the
cells still maintain normal transverse-tubule
architecture.” He adds, “We also are the first
group to discover the first and only protein
regulator (phospholemman) of sodiumcalcium exchanger in the heart.”

Dr. Cheung was elected in 1994 to the
American Society for Clinical Investigation
(ASCI), an honorific society that elects some
60 members each year for their outstanding
records of scholarly achievement in biomedical research. Throughout his career, Dr.
Cheung has always focused on cardiovascular
research. The first of his two major interests —
both of which are currently NIH funded
— explores heart cell remodeling after a heart
attack and the mechanisms by which exercise
training improves heart function in the wake
of that event.

Joseph Cheung, MD, PhD, Chief of the Division of
Nephrology, is expanding the division’s research and
clinical activities.

of nights and weekends as the other faculty
members in the division.
Born and raised in Hong Kong, Dr. Cheung
left to attend McGill in Montreal, where he
obtained a BS with First Class Honors in
Biophysics. He enrolled in the combined MDPhD program at Penn State where he obtained
his PhD in Physiology, and completed his MD
studies at Duke. It was as a first-year medical

“We measure intracellular ions, ion currents,
and the contraction of single heart cells,”
explains Dr. Cheung. He works within
Jefferson’s Center for Translational Medicine
and surgically induces heart attacks in
genetically engineered mice. “We actually
have the mice running on a treadmill,” he
explains, “in order to observe changes in the
heart after heart attack, with and without
exercise.” Apparently the mice take to the
exercise regimen rather quickly and easily.
“After three weeks, they can run quite fast,”
says Dr. Cheung. “Within eight weeks, we
start to see cellular changes.”

Sodium-Calcium Exchanger
A second major interest is the regulation of
cardiac sodium-calcium exchanger in the

https://jdc.jefferson.edu/translations/vol4/iss1/1
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Cardiac Cells in Mice

A minor interest of Dr. Cheung’s is
erythropoietin, an agent that is widely used
clinically to stimulate the growth of red
blood cells in kidney failure patients and in
patients receiving chemotherapy. “Our goal
is to answer the question, ‘How does this
work?’” he says. “More than 20 years ago, we
were the first to report that erythropoietin
increases intracellular calcium in red blood
cell precursors.” Drs. Miller and Cheung
have identified the erythropoietin-regulated
calcium permeable ion channel, which belongs
to the family of transient receptor potential
(TRP) channels. “What is translational,” says
Dr. Cheung, “is how erythropoietin promotes
cell division and survival — and our goal
is to understand the precise pathway so that
better agents can be designed with fewer
side effects.” ■
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Gift Supports Research in High Blood
Pressure and Kidney Disease
Murray I. Blackman, Trustee of the Kahn
Foundation, was kind enough to support
Joseph Cheung, MD, PhD, in his work on
chronic kidney diseases, and specifically, on
ion transport in patients with high blood
pressure (hypertension).
“High blood pressure is the most common
cause of chronic kidney disease and kidney
failure,” explains Dr. Cheung. “One-third of
patients with kidney failure who are currently

treated with dialysis have hypertension as the
causative event.” Mr. Blackman’s generous gift
supports his research in studying the mechanism
of how a particular molecule is regulated. Dr.
Cheung is hopeful that this research will provide
a window through which to see the pathway
of how hypertension causes kidney disease.

smooth muscle cells can cause stiffening of
blood vessels and subsequent development
of high blood pressure.” One of the ion
transporters is sodium-calcium exchanger —
a target of Dr. Cheung’s research for several
years, which has been intimately related to ion
homeostasis in vascular smooth muscle. ■

“One way to look at hypertension is to study
smooth muscle cells,” says Dr. Cheung.
“Alteration of ion homeostasis in vascular

Cath Lab Dedication
On May 14, 2008, Jefferson hosted the
dedication of a newly renovated catheterization laboratory (Cath Lab) with the
corporate donor who funded the renovation
with a $500,000 donation. The donor, N. J. Sky
Cooper, is President/CEO of Charles Jacquin et
Cie, Inc., America’s oldest producer of cordials,
operating in Philadelphia since 1884. ■

(Left to right) Arthur Feldman, MD, PhD, Magee
Professor and Chair of Medicine; Bernard L. Segal,
MD, Director Emeritus, Division of Cardiology; N. J.
Sky Cooper, President and CEO of Charles Jacquin et
Cie, Inc.; Michael Savage, MD, Co-Director, Cardiac
Catheterization Lab; and Tom Lewis, President and
CEO of Thomas Jefferson University Hospital

Education

Clerkship Director Gretchen Diemer:
Shaping the Med Student Experience
As Clerkship Director and Assistant
Residency Program Director for Internal
Medicine, Gretchen Diemer, MD, has a
direct impact on the career of every thirdyear student in the Internal Medicine
program at Jefferson — which totals more
than 250 people this year alone.
After attending the University of Virginia
Medical School and doing an internship
and residency at Penn, Dr. Diemer came to
Jefferson in 2004 and worked as a Hospitalist
in Internal Medicine — a hospital-based specialty that focuses on
improving the quality
of care for inpatients.
Gretchen Diemer, MD,
directs the Internal
Medicine Clerkship
program, to enrich
third-year students’
clinical experiences.

Dr. Diemer assumed her current role of
Internal Medicine Clerkship Director in 2007,
and finds her work in medical education
to be a challenging and satisfying way to
support the next generation of physicians.
The Internal Medicine Clerkship program,
which she oversees, takes place during the
students’ third year. This is a period of
intense clinical experience, “when the students
do what are essentially apprenticeships,”
she says. “The idea is for each student to
be exposed to a number of areas, to gain a
strong understanding of internal medicine
— regardless of a particular specialty.”
The students rotate at Jefferson University
Hospital for four of the 12 weeks of the
clerkship, and for the other eight weeks rotate
through one of seven other affiliated hospitals:
Christiana Hospital in Delaware, York
Hospital, Reading Hospital, UPMC Mercy
in Pittsburgh, Methodist Hospital, Albert
Einstein Medical Center, and the Wilmington

Published by Jefferson Digital Commons, 2010
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VA Medical Center. Dr. Diemer helps the
site directors to structure the program so that
all students receive a consistent experience.
“There’s a strong correlation between the
quality of a student’s clerkship and the
specialty that he or she ultimately chooses, so
we take this part of the process very seriously.”
She is also constantly seeking to recruit new
sites to the clerkship program.
Dr. Diemer is also involved in curriculum
development for the residency program and
oversees evaluations that are written for
every resident in the program. She spends
time planning with medical students who are
at the end of their third year, in terms of what
electives to take. In addition, her position
includes a fair amount of career advising. “I
really enjoy my job,” Diemer says, “because
Jefferson is a place that values education. It’s a
pleasure to work at an institution that is committed to devoting resources to programs that it
deems as so crucial to its mission.” ■
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Rheumatology

New Director Builds on
Centers of Excellence
The Division of Rheumatology is growing
and expanding under the leadership of its
new Director, Oscar Irigoyen, MD. Named
to the position in July 2008, Dr. Irigoyen had
served as Acting Director since the spring of
2007 and previously served as the Clinical
Rheumatology Director.
Born and raised in Argentina, Dr. Irigoyen
received a doctor of medicine degree
from Buenos Aires University School of
Medicine and completed a residency in
Internal Medicine at the Medical Research
Institute of Buenos Aires. He completed his
fellowship in Rheumatology at the College of
Physicians and Surgeons (P & S) of Columbia
University in New York. He subsequently
served as Assistant Professor at Columbia
P & S Medicine and at the Albert Einstein
College of Medicine. In 1987, he returned to
Columbia University and rose to Associate
Clinical Professor of Medicine, a position he
held until coming to Jefferson in 2006.
Dr. Irigoyen explains that Jefferson is a major
referral center for rheumatology in the tri-state
area. “Much of the emphasis in the division
now is clinical – seeing patients and doing
clinical research,” he says. The size of the division is currently five faculty members, and Dr.
Irigoyen seeks to recruit additional physicians
in order to meet the increasing demand.

Disease-Specific Centers
To ensure the best of care the Division of
Rheumatology has continued to expand
and create new disease-specific Centers
of Excellence. “The patients who move in
and out of Jefferson every day are actively
involved in their own education about their
health,” says Dr. Irigoyen, “and we are
constantly striving to improve the programs
and resources we make available to them.”
In May 2008 two of Rheumatology’s centers
were highlighted in Philadelphia magazine as
Centers of Excellence: Jefferson Osteoporosis
Center and the Lupus Center at Jefferson.
Although the Jefferson Osteoporosis Center
is located in Bala-Cynwyd and the Lupus
Center is located in Center City, consultation
services for those conditions are provided at
both locations.

The Arthritis Center treats patients
with inflammatory disorders, including
rheumatoid arthritis and psoriatic arthritis.
These chronic conditions are characterized
by inflammation of the lining of the joints (in
rheumatoid arthritis) and inflammation of
the skin and joints in psoriatic arthritis (also
known as psoriasis when it affects only the
skin). “In the past we could never get patients
into complete remission; the treatment we
had available would not completely prevent
progressive damage to the joints,” he says.
“With the advent of the new biologicals,
now the majority of patients can go into
remission within 4 to 8 weeks, depending on
the medication.” Some of these new drugs are
administered intravenously at the Division’s
Infusion Centers at Bala-Cynwyd and Center
City. The centers also treat conditions such as
uveitis, an inflammation of the eye, as well as
other dermatological conditions. Dr. Irigoyen
explains that “new types of medications
developed in just the past few years make a
huge difference for patients.”

Research Studies
The Osteoporosis, Arthritis, and Lupus
Centers are currently participating in
clinical research studies on the conditions
of osteoporosis, rheumatoid arthritis,
scleroderma, and lupus. Rheumatology also
collaborates with other Jefferson departments
and divisions on a number of projects. One
of the collaborations is with Dr. Charlene
Williams in the Center for Translational
Medicine, to identify gene abnormalities in
conditions classified as autoinflammatory
or in conditions that cannot be classified.
“Symptoms of these conditions range
from recurrent fevers to rashes that have
no apparent explanation,” Dr. Irigoyen
says. “Our hope is to identify specific gene
abnormalities, so that we can diagnose the
disease more effectively, and understand the
mechanisms of the disease, which can lead to
a more rational treatment.”
Dr. Irigoyen emphasizes that this has been a
time of growth for the division. The Infusion
Centers have been expanded and renovated,
and the planning process is underway for
construction of a new clinical area at the
Center City location on the 6th floor of
Walnut Towers.

https://jdc.jefferson.edu/translations/vol4/iss1/1
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Oscar Irigoyen, MD, Director, Division of
Rheumatology, plans to expand the division and
improve disease-specific centers to meet increased
patient demand.

“This is a time of movement forward and
expansion, as we strive to make our clinical
centers the best in Philadelphia as well as
Pennsylvania,” Dr. Irigoyen says. ■

Prestigious $11.6M Grant Supports Study
of Heart Failure, continued from page 1
Dr. Koch’s group will focus on the role of
the enzyme GRK5 in regulating gene transcription and growth of heart cells, which
can cause cardiac enlargement and heart
failure. A group led by Arthur Feldman,
MD, PhD, Magee Professor and Chair of the
Department of Medicine, focuses on the role
of signaling through the heart’s adenosine
receptors. A third group is led by Thomas
Force, MD, James C. Wilson Professor of
Medicine and Clinical Director of the Center
for Translational Medicine, and will continue
studies of cancer drugs called tyrosine kinase
inhibitors to understand how they affect heart
cells including cardiac stem cells. ■
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Cardiology

Preparing for the Future of Clinical Medicine:
Pay-for-Performance Programs
Jefferson University Physicians (JUP)
participated in a pilot project from July
through December 2007 called the Physician
Quality Report Initiative (PQRI), sponsored
by the Centers for Medicare and Medicaid
Services (CMS). This quality initiative aims to
measure and improve physicians’ performance
in ambulatory care (outpatient) settings.
Many of the JUP practices agreed to participate,
and although the project is ongoing, CMS
has reported on the initial period. Assistant
Director of Clinical Outcomes Research,
Suzanne Adams, RN, MPH, supported PQRI
for the Division of Cardiology and explains
that the Division had both the highest level
of participation and the best performance
ratings of those Jefferson practices involved,
including Family Medicine, Anesthesiology,
Dermatology, and other medical and surgical
sub-specialties. “We are proud to report that
a total of 31 Jefferson Heart Institute (JHI)

physicians participated, and of those, 27 met
the PQRI standard,” she says. Some of the
cardiology quality indicators this project
evaluates include evidence-based medication
management and appropriate testing for
common diagnoses such as myocardial
infarction and heart failure.

in the current economic climate,” says Adams,
“strong PQRI performance means that practices like ours will not be affected because we
meet that quality standard. This translates into
a standards-based clinical environment that
will stave off reimbursement cuts.”

PQRI is related to a new value-based purchasing
initiative that CMS intends to implement,
where the organization takes a closer look at
the services for which reimbursements are
requested. The quality performance measures
address over 180 diagnoses.

“This is an important model not just for
Medicare, but for all private payors who are
playing an increasingly significant role in
medical care,” says Adams. Insurers such as
Aetna and Independence Blue Cross are right
behind CMS in terms of the same process of
measuring and enhancing quality of care.

The advantage to strong performance in this
initiative is that it strengthens the position of
Cardiology to become eligible for reimbursement on Medicare billing, and also to measure
and respond to quality indicators. However,
there is also a prognostic side to the program.
“When it’s time for cutbacks, as is inevitable

“We are pleased that the Jefferson Cardiology
Group has worked together so effectively to
achieve such strong performance — from
doctors and clinicians to billing and administration staff,” Adams says. “At JHI we will
continue with this ongoing initiative, always
striving higher for optimal standards of care.” ■

Faculty News

Awards and
Honors
Paul Bray, MD, Thomas Drake Martinez
Cardeza Professor of Medicine and Director
of the Division of Hematology, has coauthored a research study indicating that
postmenopausal women can take a simple
blood test to determine whether hormone
therapies present an elevated risk of heart
attack. The paper was published in the
April 3, 2008, issue of the American Journal
of Cardiology. The study was part of the
Women’s Health Initiative sponsored by the
National Heart, Lung, and Blood Institute of
the National Institutes of Health (NIH).
Sharon Rubin, MD, Associate Professor of
Cardiology, received a Humanitarian Award
from Jefferson Medical College on Awards
Day, May 29, 2008.
Paul Mather, MD, Professor and Director
of the Advanced Heart Failure and Cardiac
Transplant Center at the Jefferson Heart

Right (left to right):
Arthur Feldman, MD,
PhD, Chair of Medicine;
Dr. Moon; David Nash,
MD, MBA, Founding
Dean of the new
School of Population
Health; and Albert
Worthington, Director
of Health Information
Management.

Center, has been chosen to serve as the
program co-chair for the 2010 American
College of Cardiology Annual Meeting.
Kathleen Squires, MD, Director of
the Division of Infectious Diseases and
Environmental Medicine, was appointed
Chairperson of the NIH AIDS Clinical
Studies and Epidemiology (ACE) Study
Section. The term runs July 2008–June 2010.
Behzad Pavri, MD, Associate Professor
of Cardiology, was invited to serve as the
keynote speaker for the inauguration of the
Therapy and Procedure Training Center in
Chennai, India in July 2008. ■
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Leon Peris Award
On June 11, Jefferson Medical College
presented the 2008 Leon A. Peris Memorial
Award to Alfred O. Moon, MD, a graduating
internal medicine resident. The award is
given to a graduating resident who exhibits
excellence in the completion of medical
records. Dr. Moon is pursuing an Allergy and
Clinical Immunology Fellowship at Kaiser
Permanente in Southern California. ■
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Welcome New Faculty
The following faculty members have joined the
Department of Medicine as of January 2009:
Cardiology
Deborah August, MD
Kimberly French, MD
Gregory Marhefka, MD
Center for Translational Medicine
David M. Harris, PhD
Jifen Li, PhD
Gastroenterology
Bob Etemad, MD
Marianne Ritchie, MD

Hematology
Michael Holinstat, PhD
John Kark, MD

Infectious Disease
Deena Athas, MD
William Short, MD

Internal Medicine
William Chong, MD
Allison Johnson, MD
Joanna Kipnes, MD
Mary Kate McCullen, MD
Rola Rimawi, MD
Justin Vadaparampil, MD
Jennifer Valentine, MD

Nephrology
Stephanie DeLoach, MD
Dan Negoianu, MD
Pooja Singh, MD
Pulmonary/Critical Care/Sleep
Ritu G. Grewal, MD
Rheumatology
Michele Meltzer, MD

ACC Poster Competition Winners
Faculty member David Axelrod, MD (far left), Residency Program Director
Gregory Kane, MD (4th from right), and Department Chair Arthur Feldman,
MD, PhD, congratulate students and physicians in training who won
honors at the American College of Cardiology poster competition (see
background), including graduating JMC seniors (from left to right) Nisha
Aggarwal, Katie Hawthorne, Erin Toto, and Mahdi Chowdhury as well as
3rd-year medical resident Paul Sagar, MD (2nd from right) and cardiology
fellow Siva Kumar, MD (3rd from left). Not pictured: David Whellan, MD,
MHS, Director of Clinical Outcomes Research.
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Endocrinology, Diabetes,
and Metabolic Diseases
Serge A. Jabbour, MD, Interim Director
Gastroenterology and Hepatology
Anthony J. DiMarino, MD, Director
Hematology
Paul F. Bray, MD, Director
Hematology/Cardeza Foundation
for Hematologic Research
Infectious Diseases and
Environmental Medicine
Kathleen E. Squires, MD, Director
Center for Biodefense
Center for Human Virology
Internal Medicine
Barry S. Ziring, MD, Director
Center for Vascular Diseases
Nephrology
Joseph Y. Cheung, MD, PhD, Director
Center for Novel Therapies
in Kidney Disease
Rheumatology
Oscar Irigoyen, MD, Director
Center for Translational Medicine
Walter
J. Koch, PhD, FAHA, Director,
https://jdc.jefferson.edu/translations/vol4/iss1/1
Vice Chair for Research, and
W.W. Smith Professor of Medicine
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